Basilea Pharmaceutica, a spin-off from Switzerland pharmaceutical company Roche, has sold eczema drug Toctino to Stiefel, part of GlaxoSmithKline for £146m ($228.4m) upfront payments and up to £50m in milestone payments.

Basilea was founded in 2000 as a spin from Swiss pharmaceutical group Roche and it went public on the SIX Swiss Exchange in 2004.

According to news provider Bloomberg, Roche retained a stake in Basilea after it spun-off from the company. Bloomberg quoted , Basilea’s chief financial officer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?